USA – Gilead Sciences, Inc. has once again secured the top position as the leading philanthropic funder of HIV-related programs globally and in the U.S., according to the latest report by Funders Concerned About AIDS (FCAA).
This annual Philanthropic Support to Address HIV and AIDS report, considered the most comprehensive of its kind, analyzed data from over 5,000 grants, disbursed by 187 funders to 2,800 grantee organizations.
In the 2023 report, which examined 2021 funding data, Gilead emerged as the foremost contributor, distributing nearly US$240 million across 1,000 HIV-related grants.
Daniel O’Day, Chairman and CEO of Gilead Sciences, emphasized the company’s dedication to health equity, driving its philanthropic contributions.
O’Day stated, “We know that progress against HIV depends on more than scientific innovation, which is why we support the community organizations doing remarkable work to eliminate barriers to care.”
This commitment aligns with Gilead’s broader vision to contribute significantly to ending the global HIV epidemic.
Gilead’s philanthropic impact extends beyond its overall leadership, earning the company top positions across various categories.
The company is recognized as the number one funder of BIPOC (Black, Indigenous, People of Color) communities in the United States, supporting gay men, sex workers, transgender communities, and individuals who use drugs.
Moreover, Gilead secured the top position in funding capacity-building and leadership development programs and addressing the unique challenges posed by the COVID-19 pandemic.
The company also earned additional recognitions, ranking as the second funder of children and youth programs, women and girls programs, and PrEP (pre-exposure prophylaxis) awareness and educational programs.
Masen Davis, Executive Director of Funders Concerned About AIDS, emphasized the critical role of private philanthropy in achieving global targets for HIV and AIDS, especially in the current challenging environment.
Gilead’s impactful philanthropic efforts are channeled through signature initiatives and long-term commitments.
The COMPASS Initiative, celebrating its five-year anniversary, has committed over U$100 million to address the HIV/AIDS epidemic in the U.S. South.
RADIAN, a US$25 million partnership with the Elton John AIDS Foundation, aims to reduce new HIV infections in Eastern Europe and Central Asia.
Gilead’s HIV Age Positively Program, launched in 2018, has awarded more than US$35.8 million in grants to support over 40 community-based organizations focused on improving the quality of life for those aging with HIV.
The TRANScend Initiative supports Trans-led organizations, providing nearly US$10 million in funding since 2019.
Gilead’s Zeroing In: Ending the HIV Epidemic grant program aims to support organizations working to increase the overall health and wellness of communities most impacted by HIV and the COVID-19 pandemic, investing in 126 organizations and partners across 47 countries.
This year, Gilead introduced the Setting the P.A.C.E. Initiative, a 3-year, US$10 million commitment to increase HIV prevention, anti-stigma, and health equity efforts for Black cisgender and Transgender women and girls in the United States.
Gilead’s multifaceted approach and continued commitment underscore its pivotal role in the global fight against HIV/AIDS, showcasing leadership not only in medical innovation but also in fostering community support and health equity.